U.S. Endometriosis Treatment Market To Reach $1,284.10 Million By 2030

U.S. Endometriosis Treatment Market Growth & Trends

The U.S. endometriosis treatment market size is anticipated to reach USD 1,284.10 million by 2030 and is projected to grow at a CAGR of 11.86% from 2025 to 2030, according to a new report by Grand View Research, Inc. Endometriosis, characterized by the presence of tissue similar to the uterine lining outside the uterus, is increasingly recognized as a critical health concern. Affecting 2% to 10% of women aged 25 to 40 in the United States, according to Johns Hopkins Medicine, the condition imposes significant physical, emotional, and economic burdens on patients, often reducing their quality of life and limiting their participation in daily activities.

The growing prevalence of endometriosis has catalyzed demand for innovative treatments that address unmet medical needs. Pharmaceutical companies are actively developing targeted therapies to improve outcomes for affected individuals. For example, Pfizer Inc. and Myovant Sciences achieved a key milestone with the FDA approval of MYFEMBREE in August 2022, a novel oral therapy designed to treat moderate to severe pain in premenopausal women. This approval reflects the industry's commitment to addressing the specific challenges of endometriosis patients.

Public awareness campaigns also contribute significantly to market growth by emphasizing early diagnosis and timely treatment. Initiatives such as Endometriosis Awareness Month, observed annually by the New York State Department of Health, and advocacy efforts by organizations like the Endometriosis Foundation aim to educate the public and reduce stigma surrounding the condition. These campaigns underscore the severe impact of symptoms such as chronic pain, infertility, and mental health issues, encouraging patients to seek effective care.

Investments in research and development (R&D) are accelerating market expansion. Governments, private organizations, and pharmaceutical companies are dedicating significant resources to advancing endometriosis treatment. Noteworthy examples include Sunstone Life Science Ventures’ USD 5.59 million investment in Forendo Pharma in 2019 for developing novel therapies, and AIMA Laboratories’ USD 468.5 million funding in 2022 to innovate at-home blood-testing technologies for endometriosis diagnosis. These efforts highlight the market's potential for growth through cutting-edge therapeutic and diagnostic advancements.

Despite this progress, the market faces challenges. The widespread availability of over-the-counter (OTC) and generic drugs poses a restraint on the growth of branded pharmaceuticals. Cost-conscious patients often turn to generic medications or OTC options such as NSAIDs (e.g., aspirin, naproxen, ibuprofen) for managing pain and inflammation associated with endometriosis. These accessible and affordable alternatives are commonly chosen for mild symptoms, limiting the uptake of more advanced hormonal or surgical interventions.

Overall, the market stands at a pivotal juncture, driven by increasing disease awareness, innovation in therapeutic solutions, and robust R&D investments. While affordability concerns and competition from generics remain challenges, the market's trajectory indicates significant opportunities for stakeholders to address unmet needs and improve the lives of patients.

 Request a free sample copy or view report summary: U.S. Endometriosis Treatment Market Report

U.S. Endometriosis Treatment Market Highlights

• Based on treatment type, the hormone therapy segment led the market with the largest revenue share of 78.51% in 2024. Hormone therapy is the most effective and widely prescribed treatment for managing endometriosis symptoms, particularly pain and inflammation, driving its dominance in the market.

• Based on drug class, the gonadotropin-releasing hormone (GnRH) therapies segment led the market with the largest revenue share of 51.33% in 2024. GnRH therapies are highly preferred due to their targeted mechanism of action in suppressing endometrial growth, offering significant efficacy and compliance.

• Based on route of administration, the oral segment led the market with the largest revenue share of 49.14% in 2024. The oral route is favored for its convenience, ease of use, and patient adherence, making it the leading segment for endometriosis treatments.

• Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 60.99% in 2024. Retail pharmacies are the primary distribution channel due to their widespread accessibility and role in dispensing prescription medications, especially for chronic conditions like endometriosis.

U.S. Endometriosis Treatment Market Segmentation

Grand View Research has segmented the U.S. endometriosis treatment market report based on treatment type, drug class, route of administration, distribution channel:

U.S. Endometriosis Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

• Pain Medication

• Hormone Therapy

U.S. Endometriosis Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030

• NSAIDs

• Oral Contraceptive

• Gonadotropin Releasing Hormone

• Others

U.S. Endometriosis Treatment Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Injectable

• Others

U.S. Endometriosis Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Others

List of Key Players in the U.S. Endometriosis Treatment Market

• Bayer AG

• Pfizer, Inc.

• AbbVie, Inc

• AstraZeneca

• ObsEva SA

• Teva Pharmaceutical Industries Ltd.

• Zydus Healthcare Limited

• Astellas Pharma, Inc.

• Gedeon Richter Plc.

• Takeda Pharmaceutical Company Limited